Five things for pharma marketers to know: Wednesday, March 9, 2016 – Medical Marketing and Media

Medical Marketing and Media

Five things for pharma marketers to know: Wednesday, March 9, 2016
Medical Marketing and Media
1. Amarin reached a settlement with the FDA over its off-label marketing lawsuit. As part of the settlement, the regulator will not appeal a previous court ruling in Amarin's favor. (MedPage Today). 2. Mobile health apps that have privacy policies
Amarin's Right to Promote Vascepa(R) Off-Label Affirmed Under First Amendment Litigation Settlement Terms Amarin Corporation plc

all 137 news articles »
Homecare Mechanical Ventilator Market Size, Global Industry Analysis, Medical Market Research Report 2016 – Medgadget.com (blog)

Homecare Mechanical Ventilator Market Size, Global Industry Analysis, Medical Market Research Report 2016
Medgadget.com (blog)
The Global Homecare Mechanical Ventilator Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Homecare Mechanical Ventilator industry. Firstly, the report provides a basic overview of the industry

and more »
The New Patient Centricity Demands Clarity, Community—And Confidence – Medical Marketing and Media

Medical Marketing and Media

The New Patient Centricity Demands Clarity, Community—And Confidence
Medical Marketing and Media
A while back three of us assembled to talk about the idea of patient-centricity. We'd been brought together as part of a roundtable discussion about how patient-centricity was interpreted differently across the healthcare industry. Our goal: To

Five things for pharma marketers to know: Tuesday, February 16, 2016 – Medical Marketing and Media

Medical Marketing and Media

Five things for pharma marketers to know: Tuesday, February 16, 2016
Medical Marketing and Media
1. Express Scripts said it miscalculated how many cardiologists would prescribe PCSK9 inhibitors, a new class of cholesterol-lowering drugs that includes Amgen's Repatha and Sanofi's and Regeneron's Praluent. As such, a surge in sales of the drugs is …

Five things for pharma marketers to know: Tuesday, February 9, 2016 – Medical Marketing and Media

Medical Marketing and Media

Five things for pharma marketers to know: Tuesday, February 9, 2016
Medical Marketing and Media
1. The FDA's arthritis advisory committee is scheduled to meet today to discuss Celltrion's application for a biosimilar version of Remicade, Johnson and Johnson's best-selling drug used to treat a number of indications including Crohn's disease and …

and more »
Five things for pharma marketers to know: Friday, January 29, 2016 – Medical Marketing and Media

Medical Marketing and Media

Five things for pharma marketers to know: Friday, January 29, 2016
Medical Marketing and Media
1. The FDA approved Merck's two-drug hepatitis C regimen, Zepatier, for the treatment of patients with genotypes 1 and 4. Merck gave Zepatier a list price of $54,600 for 12 weeks of treatment, according to Evercore ISI analyst Mark Schoenebaum, a $40

and more »
Marketing challenges remain in crowded metabolic market – Medical Marketing and Media

Medical Marketing and Media

Marketing challenges remain in crowded metabolic market
Medical Marketing and Media
Saxenda, originally marketed as Victoza (and prescribed to treat diabetes), is a once-daily injection for weight loss from Novo Nordisk. The off-the-charts obesity rate in the US is tailspinning into a reality of metabolic dysfunction. The call is out

and more »
Five things for pharma marketers to know: Monday, January 11, 2016 – Medical Marketing and Media

Medical Marketing and Media

Five things for pharma marketers to know: Monday, January 11, 2016
Medical Marketing and Media
1. Shire agreed to buy Baxalta for $32 billion, creating the world's largest rare-disease drugmaker. The deal will add Baxalta's hemophilia drugs to Shire's portfolio, including Advate, which can cost between $200,000 to $500,000. The accepted offer …

and more »